| Project/Area Number |
25461163
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Kagoshima University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
井上 博雅 鹿児島大学, 医歯学域医学系, 教授 (30264039)
|
|---|
| Project Period (FY) |
2013-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 喘息 / アセチルコリン / ムスカリン受容体 / 好酸球 / 気道炎症 / コリンアセチルトランスフェラーゼ / 喘息マウスモデル / アレルギー性炎症 / ムスカリン受容体（M3) |
|---|
| Outline of Final Research Achievements |
The aim of this study was to investigate the role of cholinergic inflammation in the pathogenesis of bronchial asthma. We evaluate whether the anti-cholinergic drugs, the muscalinic(M3) receptor antagonists, could control the allergic inflammation, and clarify the mechanisms of effects of M3R antagonists.
Treatment with tiotropium(TIO) on mice sensitized and challenged with OVA reduced eosinophilic inflammation and the Th2 cytokine production, and the expression of ChAT. However the expression of M3r was upregulated with TIO.
In clinical settings, the biomarker of bronchial eosinophilic inflammation in asthma patients (eg FeNO, peripheral eosinophil counts) had not change after addition of tiotropium.
|
